| Developer | Designation | Description | Development Status & Location - Indications |
|
EntreMed
Current as of: March 12, 2009 | Other Designation: ENMD-1198 | ENMD-1198, a novel tubulin binding agent, is the lead among 3 compounds that are new chemical entities based on the antitumor and antiangiogenic agent 2-methoxyestradiol (2-ME2), with a reduced rate of metabolism and improved PK and antitumor activity in animal models. Administration Route: PO | Phase I (begin 5/06, ongoing 11/08) USA; phase I (begin 05/06, ongoing 11/07) USA - solid tumors, advanced, refractory |